絞り込み

16645

広告

新型ウイルス対応医師ら職場で“バイ菌”扱い 学会が抗議声明

新型コロナウイルスの集団感染が起きたクルーズ船などで、対応を行った医師や看護師らが職場などで不当な扱いを受けているとして、災害対応を行う医療関係者でつくる学会が...

  1. 新型肺炎 インフルエンザ治療薬など使用 ...
  2. 新型肺炎 クルーズ下船後に陽性 栃木の6...
  3. 【動画】「dry cough」の意味を予...
  4. G20開幕 肺炎議題に 世界経済リスク、...

ニュース一覧

「"Perl AE"[Author]」の検索結果

46件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.

Improving response to FLT3 inhibitors--BCL2 the rescue?

Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.

Availability of FLT3 inhibitors--how do we use them?

Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia.

Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia.

Advances in patient care through increasingly individualized therapy.

Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Classes of ITD predict outcomes in AML patients treated with FLT3 inhibitors.

Phase 2b study of two dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations.

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

The role of targeted therapy in the management of patients with AML.

  1. 1
  2. 2
  3. 3
Sort by
※並べ替えは表示に時間がかかります